Amunix Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amunix Pharmaceuticals, Inc. - overview
Established
2006
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 2006 and based in California, US, Amunix Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded by Volker Schellenberger. In March 2021, Amunix raised USD 117 million in Series B funding led by Viking Global Investors.
Amunix is a biopharmaceutical company that focuses on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers. Amunix offers XPAT® and XPAC™ technology platforms to develop novel drugs that are preferentially activated in the tumor microenvironment and designed to overcome toxicity challenges that have hindered other T cell and cytokine therapies. Amunix's pipeline includes AMX-818, an XPAT® T cell engager targeting a variety of HER2-expressing solid tumors, which is currently in IND-enabling studies. Along with several other T cell engager programs, the company is also applying its proprietary masking technology to its first masked, protease-activated cytokine program, IL12-XPAC™, which is in the discovery stage.
The company plans to continue developing AMX-818, a masked, protease-activated T cell engager (XPAT®) targeting HER2-expressing solid tumors, as well as support Amunix’s pipeline of earlier-stage XPATs® and masked, protease-activated cytokines (XPACs™).
Current Investors
Frazier Healthcare Partners, Polaris Partners, Venrock
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.amunix.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.